Nexalin Technology, Inc. (NASDAQ:NXL – Get Rating) CFO Marilyn Elson purchased 9,500 shares of the stock in a transaction that occurred on Wednesday, September 28th. The shares were purchased at an average cost of $1.12 per share, for a total transaction of $10,640.00. Following the completion of the acquisition, the chief financial officer now directly owns 835,244 shares of the company's stock, valued at approximately $935,473.28. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Nexalin Technology Stock Down 1.7 %
NXL traded down $0.02 during midday trading on Thursday, hitting $1.13. 1,104 shares of the company traded hands, compared to its average volume of 793,341. Nexalin Technology, Inc. has a 52-week low of $1.09 and a 52-week high of $2.95.
Get Nexalin Technology alerts:About Nexalin Technology
(Get Rating)
Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.Read More
- Get a free copy of the StockNews.com research report on Nexalin Technology (NXL)
- This Small-Cap Healthcare Name Is Outperforming Its Index
- What Cintas Can Teach Investors About This Bear Market?
- 2 Casino Stocks Worth Taking a Look At
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.